Featured Oncology NewsDelivering A Baby Increases - Then Lowers - Risk Of Breast Cancer: Study
December 11, 2018
One Implant, Two Prices. It Depends On Who’s Paying
December 11, 2018
Peer-Spectives is a new podcast series that is moderated by our editor-in-chief Robert Figlin, MD, and
features select thought-leaders covering the latest clinical developments in a wide range of cancer settings.
Moderated by:
Steven Spielberg Family
Chair in Hematology-Oncology
Cedars-Sinai Medical Center
We explore the scope of the escalating cost of cancer care, discuss the factors that contribute to the total cost of cancer care,
and provide resources to help us all understand the facts regarding the cost of cancer care.
Sponsored by:
Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.
The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.
Combination Of Two Immunotherapies Shows Activity In Non-small Cell Lung Cancer Patients
Merck Raised Prices Five Drugs Including Keytruda In November
Side Effects From Certain Immunotherapies May Be Higher Than Initially Reported
Pipeline Online is the most comprehensive and up to date oncology pipeline information resource that is widely available on the web ...
OBR Finance tracks the market performance of oncology companies and products, and compares our performance versus other indices ...
OBR Radar is a snapshot of upcoming pivotal events in the oncology industry such as FDA action dates, anticipated announcement of pivotal clinical data, and ODAC dates ...
[by phone or online via webcast]
Dallas, TX
Houston, Texas
San Francisco, CA
San Francisco, CA
Amsterdam, The Netherlands
Santa Monica, CA
Washington, DC
Orlando, FL
Atlanta, GA
Orlando, FL
Geneva, Switzerland
Denver, CO
Chicago, IL
RAI Amsterdam, The Netherlands
Lugano, Switzerland
San Francisco, CA
Buenos Aires, Argentina
Orlando, FL
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.
Featured Content
Previous
News Story Commentary
Meet the Editorial BoardView all Commentary
AZ’ Imfinzi Fails In Head And Neck Cancer Trial
December 08th 2018 by Howard S. Hochster, MD
Once again, despite our hopes, and the imagination of the public, that a magic-bullet immunotherapy...
Read More
Genentech: FDA Approves Tecentriq in Combination for...
December 07th 2018 by H. Jack West, MD
While it's nice to have a new approval, this is also a setting in which the IMpower150 regimen offe...
Read More
This Cancer Biotech Stock Just Averted A Patent Disa...
December 05th 2018 by Debu Tripathy, MD
Very interesting
Read More
Roche's Tecentriq Wins Speedy U.S. FDA Review For Sm...
December 05th 2018 by H. Jack West, MD
This will be an important development for thoracic oncology. The results of the IMpower133 trial, w...
Read More
Seattle Genetics and Takeda Present Positive Data fr...
December 05th 2018 by William Harwin MD
Like the data
Read More
Bristol-Myers Squibb Announces CheckMate -451 Study ...
November 27th 2018 by H. Jack West, MD
This is a big miss. Though even a positive result would need to be weighed for significance relativ...
Read More
OBR Green